Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny, Inc. Chief Operating Officer Melissa B. Cummings sold 1,879 common shares at $28 per share on October 14, 2026, pursuant to a Rule 10b5-1 trading plan entered into on December 19, 2025. On the same date, 1,559 shares were withheld for payment of withholding taxes upon vesting of restricted stock units granted to her; the reported price for those shares was $27.39 per share.
Progyny, Inc. officer Melissa B. Cummings proposes to sell 1,879 common shares, with an aggregate market value of $52,612 and an approximate sale date of October 14, 2026. Fidelity Brokerage Services LLC is listed as broker. The shares are identified as restricted-stock vesting from the issuer and compensation received October 14, 2026.
Allison Swartz, Progyny, Inc.’s EVP, GC, sold 3,903 shares of common stock in a non-derivative transaction on September 23, 2026, at $26.10 per share. Her directly held position after the sale was 75,816 shares. The sale was made under a Rule 10b5-1 trading plan entered into on May 13, 2025.
Progyny, Inc. (PGNY) reports a proposed sale of 3,903 common shares for Officer Allison C. Swartz, with an aggregate market value of $101,868.30 and an approximate sale date of September 23, 2026. Fidelity Brokerage Services LLC is named as broker. The notice also lists restricted stock vesting entries of 2,398 shares on August 28, 2026, 1,047 shares on September 3, 2026, and 458 shares on September 4, 2026.
Progyny, Inc. (PGNY) reported that Chief Product Officer Geoffrey Clapp had 819 shares of common stock withheld on September 17, 2026 to cover withholding taxes due upon the vesting of restricted stock units granted to him. The tax-withholding disposition was priced at $27.38 per share, and he now holds 59,009 shares of Progyny common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
Progyny, Inc. (PGNY) director Kevin K. Gordon reported an option exercise and related share dispositions on September 10, 2026. He exercised stock options for 22,000 shares of common stock at an exercise price of $13.00 per share, from fully vested options expiring October 11, 2029. Of the resulting shares, 10,500 shares were delivered or withheld at $27.24 per share to pay the option exercise price or related tax liability, and 11,500 shares were sold at a weighted average price of $27.1181 per share in multiple trades between $26.99 and $27.24. This Form 4/A amends a prior filing solely to correct the previously reported weighted average sale price, which was originally stated as $27.9442.
Progyny, Inc. (PGNY) director Kevin K. Gordon exercised options for 22,000 shares of common stock on September 10, 2026 at an exercise price of $13.00 per share, receiving 22,000 shares. On the same date, 10,500 shares were delivered or withheld to cover the exercise price or tax liability at $27.24 per share, and 11,500 shares were sold at a weighted average price within a range of $26.99 to $27.24 per share. The options exercised were reported as fully vested, and no Rule 10b5-1 trading plan is reported.
Progyny, Inc. (PGNY) is the issuer of common stock that director Kevin Gordon plans to sell under Rule 144. A notice covers the proposed sale of 11,500 shares of common stock, expected on September 10, 2026, following a stock option exercise for cash from the issuer. The filing lists Fidelity Brokerage Services LLC as the broker for the transaction and names NASDAQ as the securities exchange.
Progyny, Inc. (PGNY) reported that Chief Executive Officer Peter Anevski had 5,361 shares of common stock withheld on September 3, 2026 to pay withholding taxes upon the vesting of restricted stock units, at a reference price of $26.29 per share. This was a tax-withholding event rather than an open-market sale. After this transaction, he holds 806,111 shares directly and an additional 1 share indirectly through PECO ANEVSKI 2020 SD LLC. No Rule 10b5-1 trading plan is reported for these transactions.
Progyny, Inc. (PGNY) executive Allison Swartz, EVP and General Counsel, reported two dispositions of common stock on September 3 and September 4, 2026, totaling 1,307 shares. The shares were withheld for payment of withholding taxes upon the vesting of restricted stock units granted to her, and no Rule 10b5-1 plan is reported.